Skip to content
10-Q

Quarterly Report

IMMUNOMEDICS, INC.

0000722830-20-000017

← back to feed
Filed
May 6, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2020 · May 1, 2020 230.9M sh
Capex Q1 2020 · Mar 31, 2020 $473K
Capex Q1 2020 · Mar 31, 2019 $2.06M
Operating Cash Flow Q1 2020 · Mar 31, 2020 −$71.87M
Operating Cash Flow Q1 2020 · Mar 31, 2019 −$54.68M
Cash And Equivalents Q1 2020 · Mar 31, 2020 $536.3M
Cash And Equivalents Q1 2020 · Dec 31, 2019 $608.63M
Cash And Equivalents Q1 2020 · Mar 31, 2019 $437.94M
Stockholders Equity Q1 2020 · Mar 31, 2020 $185.97M
Stockholders Equity Q1 2020 · Dec 31, 2019 $268.26M
Current Liabilities Q1 2020 · Mar 31, 2020 $67.11M
Current Liabilities Q1 2020 · Dec 31, 2019 $71.76M
Total Liabilities Q1 2020 · Mar 31, 2020 $409.2M
Total Liabilities Q1 2020 · Dec 31, 2019 $404.49M
Current Assets Q1 2020 · Mar 31, 2020 $561.72M
Current Assets Q1 2020 · Dec 31, 2019 $638.7M
Total Assets Q1 2020 · Mar 31, 2020 $594.11M
Total Assets Q1 2020 · Dec 31, 2019 $671.72M
Sga Expense Q1 2020 · Mar 31, 2020 $11.47M
Sga Expense Q1 2020 · Mar 31, 2019 $13.6M
Rd Expense Q1 2020 · Mar 31, 2020 $62.43M
Rd Expense Q1 2020 · Mar 31, 2019 $58.17M
Net Income Q1 2020 · Mar 31, 2020 −$93.05M
Net Income Q1 2020 · Mar 31, 2019 −$87.34M
Operating Income Q1 2020 · Mar 31, 2020 −$81.97M
Operating Income Q1 2020 · Mar 31, 2019 −$79.65M
Revenue Q1 2020 · Mar 31, 2020 $0
Revenue Q1 2020 · Mar 31, 2019 $0